FDA recommends against use of Revatio (sildenafil) in children with pulmonary hypertension
The U.S. Food and Drug Administration (FDA) is recommending that Revatio (sildenafil) not be prescribed to children (ages 1 through 17) for pulmonary arterial hypertension (PAH; high pressure in the blood vessels leading to the lungs). This recommendation against use is based on a recent long-term clinical pediatric trial showing that: (1) children taking a high dose of Revatio had a higher risk of death than children taking a low dose and (2) the low doses of Revatio are not effective in improving exercise ability.
http://www.fda.gov/drugs/drugsafety/ucm317123.htm
FDA recommends against use of Revatio in children with PAH
Модератор: Pyankov Vasily
-
- Сообщения: 5564
- Зарегистрирован: Пн ноя 24, 2008 12:59 am
- Откуда: Киров
FDA recommends against use of Revatio in children with PAH
Пьянков Василий Алексеевич
-
- Сообщения: 3258
- Зарегистрирован: Вт авг 11, 2009 5:38 pm
- Откуда: Томск НИИ кардиологии
-
- Сообщения: 5564
- Зарегистрирован: Пн ноя 24, 2008 12:59 am
- Откуда: Киров
-
- Сообщения: 1389
- Зарегистрирован: Пт янв 18, 2013 2:00 am
- Откуда: СПб. Покровская больница. Мариинская больница
Не так давно FDA немного одумались http://www.fda.gov/Drugs/DrugSafety/ucm390876.htm
С уважением, Жуковский Николай.